Table 1.
Baseline characteristics
| Overall (n = 941) | Whites (n = 608; 65%) | African Americans (n = 333; 35%) | P value | |
|---|---|---|---|---|
| Age, ya | 53 ± 17 | 54 ± 16 | 52 ± 18 | 0.843 |
| BMI, kg/m2 a | 28 ± 7 | 27 ± 7 | 29 ± 7 | <0.001 |
| Compliance, %a | 98 ± 5 | 98 ± 5 | 98 ± 6 | 0.027 |
| Male genderb | 484 (51%) | 322 (53%) | 162 (49%) | 0.206 |
| Smokera | 187 (20%) | 84 (14%) | 103 (31%) | <0.001 |
| CYP3A4*22 | ||||
| allele frequency | 0.03 | 0.04 | 0.01 | 0.003 |
| CYP3A5*3 | ||||
| allele frequency | 0.73 | 0.93 | 0.35 | <0.001 |
| SLC01B1 521 C | ||||
| allele frequency | 0.10 | 0.14 | 0.02 | <0.001 |
BMI, body mass index; CYP3A4, the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 4; CYP3A5, the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 5; SLCO1B1, the gene encoding solute carrier organic anion transporter family member 1B1.
a
Continuous variables are represented as median ± interquartile range and compared using the Wilcoxon rank sum test. bCategorical variables are represented as count (%) and compared using the chi‐square test or Fisher's exact where necessary. Bolded P values were significantly associated with low‐density lipoprotein cholesterol lowering response to simvastatin in the Cholesterol and Pharmacogenetics clinical trial.